- Home
- XCH vs COLL Comparison
XCH vs COLL Comparison
Compare XCH & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XCH
- COLL
- Stock Information
- Founded
- XCH 2015
- COLL 2002
- Country
- XCH China
- COLL United States
- Employees
- XCH N/A
- COLL N/A
- Industry
- XCH
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- XCH
- COLL Health Care
- Exchange
- XCH NYSE
- COLL Nasdaq
- Market Cap
- XCH 887.6M
- COLL 1.1B
- IPO Year
- XCH 2024
- COLL 2015
- Fundamental
- Price
- XCH $1.97
- COLL $30.78
- Analyst Decision
- XCH
- COLL Strong Buy
- Analyst Count
- XCH 0
- COLL 6
- Target Price
- XCH N/A
- COLL $42.00
- AVG Volume (30 Days)
- XCH 78.1K
- COLL 439.3K
- Earning Date
- XCH 01-01-0001
- COLL 11-07-2024
- Dividend Yield
- XCH N/A
- COLL N/A
- EPS Growth
- XCH N/A
- COLL 757.11
- EPS
- XCH N/A
- COLL 2.16
- Revenue
- XCH $42,278,856.00
- COLL $599,245,000.00
- Revenue This Year
- XCH N/A
- COLL $13.20
- Revenue Next Year
- XCH N/A
- COLL $17.63
- P/E Ratio
- XCH N/A
- COLL $14.32
- Revenue Growth
- XCH 30.65
- COLL 9.62
- 52 Week Low
- XCH $6.40
- COLL $28.97
- 52 Week High
- XCH $30.47
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- XCH N/A
- COLL 48.70
- Support Level
- XCH N/A
- COLL $29.67
- Resistance Level
- XCH N/A
- COLL $31.10
- Average True Range (ATR)
- XCH 0.00
- COLL 0.98
- MACD
- XCH 0.00
- COLL 0.26
- Stochastic Oscillator
- XCH 0.00
- COLL 69.41
About XCH XCHG LIMITED SPONSORED EACH ADS REPRESNTNG 40 CLASS A
XCHG Ltd engaged in designing, manufacturing and selling of Electric Vehicle (EV) chargers and EV charging solutions which include the DC fast chargers named the C6 series and the C7 series, the battery-integrated DC fast chargers which is Net Zero Series (NZS), as well as accompanying services. Its integrated solution combining proprietary charging technology, energy storage technology and accompanying services significantly improves EV charging efficiency and unlocks the value of energy storage and management. Its NZS solution enables fast charging at low power locations or vis-a-vis aged grid infrastructures (which typically are not compatible with fast charging equipment) with no site improvements or grid upgrades needed.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.